Chronic Lymphocytic Leukemia: State of the Art and Beyond

Restricted access

In the treatment of chronic lymphocytic leukemia (CLL), select genomic studies can assist in risk stratification of newly diagnosed patients. Chemoimmunotherapy targeting CD20 offers a survival advantage in symptomatic patients both with and without these high-risk genetic features, though patients with del(17p13.1) have poor outcomes and require specific intervention. Obinutuzumab plus chlorambucil is a treatment standard for untreated elderly patients and is superior to rituximab plus chlorambucil. In the setting of relapsed CLL, the new kinase inhibitors have the potential to completely change the treatment paradigm of CLL.

Correspondence: John C. Byrd, MD, The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, 455 Wiseman Hall, 400 West 12th Avenue, Columbus, OH 43210. E-mail: john.byrd@osumc.edu
  • 1.

    FischerKBahloJFinAM. Extended followup of the CLL8 protocol, a randomized phase III trial of the German CLL Study Group comparing fludarabine and cyclophosphamide to FC plus rituximab for previously untreated patients with chronic lymphocytic leukemia: results on survival, progression-free survival, delayed neutropenias and secondary malignancies confirm superiority of the FCR regimen [abstract]. Presented at the 2012 American Society of Hematology Annual Meeting; December 8-11, 2012; Atlanta, Georgia. Abstract 435.

    • Search Google Scholar
    • Export Citation
  • 2.

    EichhorstBWendtnerCM. Chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab in previously untreated and physically fit patients with advanced chronic lymphocytic leukemia: results of a planned interim analysis of the CLL10 trial, an international, randomized study of the German CLL Study Group [abstract]. Presented at the American Society of Hematology Annual Meeting; December 7-10, 2013; New Orleans, Louisiana. Abstract 526.

    • Search Google Scholar
    • Export Citation
  • 3.

    GoedeVFischerKBuschR. Obinutuzumab plus chlorambucil in patient with CLL and coexisting conditions. N Engl J Med2014;370:11011110.

  • 4.

    ByrdJCFurmanRRCoutreSE. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med2013;369:3242.

  • 5.

    O’BrienSFurmanRRCoutreSE. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: an open-label, multicenter, phase 1b/2 trial. Lancet Oncol2014;15:4858.

    • Search Google Scholar
    • Export Citation
  • 6.

    FurmanRRSharmanJPCoutreSE. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med2014;370:9971007.

  • 7.

    O’BrienSLamannaNKippsTJ. A phase II study of the selective phosphatidylinositol 3-kinase delta inhibitor idelalisib in combination with rituximab in treatment-nairve patients with chronic lymphocytic leukemia or small lymphocytic lymphoma [abstract]. Presented at the 2013 ASCO Annual Meeting; May 31-June 4, 2013; Chicago, Illinois. Abstract 705.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 42 42 8
PDF Downloads 10 10 0
EPUB Downloads 0 0 0